Skip to content
Open access

Drosophila proteins as human surrogates for early drug discovery: Findings from detailed structural analysis

2026 · Journal of emerging investigators · 0 citations · 37 references

TL;DR

The sequence and structural similarity between Drosophila and human proteins was examined to address the question of whether Drosophila proteins can be used as human surrogates for early drug discovery, and it was hypothesized that the sequence identity within the drug binding pocket of D. melanogaster proteins would exceed 50% when compared to their human homologs.

Abstract

Drug discovery is a complex process involving various methods used to identify biological or chemical entities that can modify the function of specific proteins believed to play a role in disease. Drosophila melanogaster, or fruit fly, has been used by researchers for over a century to study human biology, genetics of human disease, and to find new medicines. Proteins from non-human species are utilized in the early stages of drug discovery when they share high sequence similarity with human homologs and are more accessible than human proteins. This study examined the sequence and structural similarity between Drosophila and human proteins to address the question of whether Drosophila proteins can be used as human surrogates for early drug discovery. We hypothesized that the sequence identity within the drug binding pocket of D. melanogaster proteins would exceed 50% when compared to their human homologs. To assess this hypothesis, we compared five protein sequences and crystal structures from D. melanogaster complexed with approved drugs or potential drug candidates to their human homologs. The overall sequence identity between the 2 species ranged from 38 to 71%, with good structural overlap. In the drug binding pocket, the sequence identity was 55 to 100%, supporting the hypothesis. However, we also identified cases where amino acids were not conserved in functionally critical regions, limiting the use of certain Drosophila proteins for identifying human therapeutic agents. The approach described here sheds light on the diverse aspects that must be considered when selecting proteins to address drug discovery questions.

Read PDF

Similar papers

Open access Sep 2026

Development of a Translational Assay for Identification and Quantitation of Orthologous Proteins to Aid Drug Development in Preclinical Models

A modular mass spectrometry-based assay for the analysis of orthologous proteins across species in the context of translational science using ataxin-2 (ATXN2) as an example provides a translational blueprint that can be adapted to other orthologues, reducing cost and timeline in drug development.

Blandine Rougemont, Julie Borgel, Zoe Walker et al. · 0 citations
Open access Sep 2026

Structure-function analysis of PI3K signalling cascade base editing screens in cancer cells

Large-scale CRISPR base editing mutagenesis screens across 30 PI3K pathway proteins in three disease-relevant cancer cell models establish high-throughput base editing mutagenesis combined with structural analysis as a scalable strategy to delineate structure–function relationships and inform drug development.

Katrina McCarten, Bárbara Abreu, Benoit Baillif et al. · 0 citations
Open access 2026

Molecular docking as a tool in drug discovery and protein-ligand interaction analysis

Molecular docking emerged as an irreplaceable technique of structure-based drug design, revolutionizing the early stages of modern drug discovery since its introduction in the 1980s. Docking is widely used in the rational drug development to estimate binding affinity of newly designed compounds to active sites of selec...

J. Savić, M. Miličević, V. Dobričić et al. · 0 citations
Open access Sep 2026

Computational prescreening of anticancer drugs prior to in vitro validation, primarily in dogs with exploratory cat data, based on cross-species binding conservation.

Advances in veterinary medicine have prolonged the lifespan of companion animals. As a result, the burden of neoplastic diseases has increased. While targeted anticancer drugs are widely used in human oncology, their clinical translation to companion animals remains limited. Therefore, a systematic framework for priori...

Seoung-Woo Lee, Hee-Yeon Kim, Seong-Kyoon Choi et al. · 0 citations
Conference Aug 2026

Similarity-Aware BERT Model for Drug-Target Interaction Prediction

Modern drug discovery relies on accurate computational methods for predicting drug-target interactions. When trained on hundreds of millions of protein sequences, transformer-based methods such as ProteinBERT demonstrate high accuracy in predicting protein function and structural properties, including disordered region...

D. Bock, S. Grozdanić, Vladimir Jacimovic et al. · 0 citations
Oct 2026

Integrated expression profiling and structure-based drug discovery identify EGFR as a druggable target and Tripterygium wilfordii phytochemicals as potential therapeutics for autosomal dominant polycystic kidney disease.

An integrated computational framework combining microarray-based gene expression profiling, network pharmacology, and structure-based drug discovery identifies EGFR as a potential therapeutic target in ADPKD and highlights Luteolin and Triptonolide as computationally prioritized phytochemical lead candidates for furthe...

I. U. Haq, Israr Hussain, A. Mohammad et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.